The components of drug-linker conjugates for antibody drug conjugates (ADCs) are a cytotoxic drug that is active and a suitable linker. These conjugates can be used to create ADCs, which are highly selective and cytotoxic agents that are targeted for cancer cells after being joined to a monoclonal antibody.
The drug units in drug-linker conjugates are tubulin inhibitors and DNA damaging agents that have antitumor activity (i.e., ADC cytotoxins or payloads). Auristatins and Maytansinoids are the most widely used tubulin inhibitors, while Duocarmycins, Pyrrolobenzodiazepines, Camptothecines, and Daunorubicins/Doxorubicines are the most frequently used DNA damaging agents in ADCs. Additionally, a variety of conventional cytotoxic agents can be used in ADCs.
Cleavable and noncleavable ADC linkers are the two categories into which the majority of those currently undergoing clinical evaluation fall. Noncleavable linkers necessitate proteolytic degradation of the antibody component of the ADC in order to release the cytotoxic molecule, whereas cleavable linkers depend on cellular processes to release the toxin.
Structure | Cat No. | Product Name | CAS No. | Product Description |
---|---|---|---|---|
V76159 | (1R)-Deruxtecan | 2270986-87-1 | (1R)-Deruxtecan is a drug linker conjugate of ADC. | |
V53011 | (Aminooxy)acetamide-Val-Cit-PAB-MMAE | 2446645-88-9 | (Aminooxy)acetamide-Val-Cit-PAB-MMAE (MMAE 5) is an intermediate used in the synthesis/preparation of drug-linker conjugates for the preparation of ADCs. | |
V77364 | (Rac)-Lys-SMCC-DM1 ((Rac)-Lys-Nε-MCC-DM1) | (Rac)-Lys-SMCC-DM1 ((Rac)-Lys-Nε-MCC-DM1) is the racemate of Lys-SMCC-DM1. | ||
V54777 | 2',3'-cGAMP-C2-PPA | 2586047-11-0 | 2',3'-cGAMP-C2-PPA is a cyclic dinucleotide stimulating protein of interferon genes (STING) agonist. | |
V51701 | 680C-91 | 163239-22-3 | TDO inhibitor | |
V77295 | Ac-Lys-Val-Cit-PABC-MMAE formic | Ac-Lys-Val-Cit-PABC-MMAE (formic) is part of the antibody conjugate active molecule ADC. | ||
V35242 | AcLysValCit-PABC-DMAE-SW-163D | 2411007-69-5 | AcLysValCit-PABC-DMAE-SW-163D is part of the active antibody coupling molecule (drug-linker conjugates for ADC), which is made up of natural dual intercalator SW-163D and linker AcLysValCitPABC-DMAE coupling. | |
V88381 | Amino-PEG4-GGFG-Dxd | 2879227-88-8 | Amino-PEG4-GGFG-Dxd (Compound 13-7) is a drug-linker conjugate composed of Dxd and linker, which can be used for the synthesis of ADC. | |
V88382 | Aminocaproyl-Val-Cit-PABC-MMAE | 1374407-35-8 | Aminocaproyl-Val-Cit-PABC-MMAE is a drug-linker conjugate used in the synthesis of ADC. | |
V88401 | APN-PEG5-VC-PAB-MMAE | APN-PEG5-VC-PAB-MMAE is the drug-linker conjugate portion of INA03, a transferrin-competitive antibody-drug conjugate targeting CD71. | ||
V3218 | ATAC21 | 2101204-23-1 | ATAC21 is a linker immunostimulatory compound formed by conjugating a non-cleavable (non-degradable) maleimide-PEG4 linker containing a succinimide group to an immunostimulatory compound. | |
V77219 | Azide-PEG4-VC-PAB-Doxorubicin | Azide-PEG4-VC-PAB-Doxorubicin is made up of linker Azide-PEG4-VC-PAB and toxic molecule Doxorubicin, and may be utilized to prepare antibody-drug-conjugates/ADCss. | ||
V54765 | Azido-PEG4-Val-Cit-PAB-MMAE | 1869126-64-6 | Azido-PEG4-Val-Cit-PAB-MMAE is part of the antibody conjugate active molecule (drug-linker conjugate for ADC). | |
V54800 | Barzuxetan (CHX-A''-DTPA-NCS) | 157380-45-5 | Barzuxetan may be utilized in study/research of cancer diseases. | |
V52994 | Bi-Mc-VC-PAB-MMAE | 1620837-70-8 | Bi-Mc-VC-PAB-MMAE is made up of ADC linker (Fmoc-Val-Cit-PAB) and MMAE, which is a potent (tubulin) inhibitor. | |
V76161 | Biotin-PEG7-Maleimide | 1898221-65-2 | Biotin-PEG7-Maleimide is a biotinylation reagent that reacts with thiol (SH) groups. | |
V84764 | Boc-Lys-PEG8-N-bis(D-glucose) | 2892350-30-8 | ||
V51374 | Br-Val-Ala-NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT | 2857037-70-6 | drug-linker conjugate for ADC | |
V34086 | CL2-SN-38 | 1036969-20-6 | CL2-SN-38 is a cleavable linker-drug conjugate used for the synthesis of antibody drug conjugates (ADC). | |
V33342 | CL2A-SN-38 | 1279680-68-0 | CL2A-SN-38, an SN-38 (topoisomerase-I inhibitor) analogue, is a peptide-based drug linker used to synthesize antibody drug conjugates (ADC). |